About Elite Pharmaceuticals (OTCMKTS:ELTP)
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is principally engaged in the development and manufacture of oral, controlled-release products. The Company develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA's) for generic products and New Drug Applications (NDA's) for branded products. The Company owns approximately six different approved ANDA's. The Company's product, SequestOx, is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone, which incorporates five milligram, 10 milligram, 15 milligram, 20 milligram and 30 milligram doses of oxycodone into capsules. SequestOx is used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.
Industry, Sector and Symbol
Industry Drug Manufacturers - Other
Trailing P/E Ratio-11.12
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$9.64 million
Price / Sales9.10
Cash Flow$0.00 per share
Price / Cash23.75
Book Value$0.03 per share
Price / Book3.71
Net Income$3.81 million
Return on Equity-12.15%
Return on Assets-5.49%
Elite Pharmaceuticals (OTCMKTS:ELTP) Frequently Asked Questions
What is Elite Pharmaceuticals' stock symbol?
Elite Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELTP."
When will Elite Pharmaceuticals make its next earnings announcement?
Who are some of Elite Pharmaceuticals' key competitors?
Some companies that are related to Elite Pharmaceuticals include vTv Therapeutics (VTVT), T2 Biosystems (TTOO), Miragen Therapeutics (MGEN), Immune Design (IMDZ), DURECT (DRRX), Otonomy (OTIC), Synlogic (SYBX), Cogentix Medical (CGNT), Recro Pharma (REPH), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Verona Pharma plc - American Depositary Share (VRNA), Viking Therapeutics (VKTX), Sierra Oncology (SRRA), Spero Therapeutics (SPRO), Compugen (CGEN), Summit Therapeutics (SMMT) and Genesis Healthcare (GEN).
Who are Elite Pharmaceuticals' key executives?
Elite Pharmaceuticals' management team includes the folowing people:
- Nasrat Hakim, Chairman of the Board, President, Chief Executive Officer (Age 53)
- Jerry I. Treppel, Chairman of the Board (Age 60)
- Carter Julian Ward CPA, Chief Financial Officer, Treasurer, Secretary (Age 51)
- Douglas Plassche, Executive Vice President - Operations (Age 52)
- Ashok G. Nigalaye Ph.D., Chief Scientific Officer, Director (Age 62)
- George Kenneth Smith, Vice President
- Davis S. Caskey, Director (Age 65)
- Jeenarine Narine, Director (Age 64)
- Eugene M. Pfeifer, Director (Age 76)
- Barry H. Dash Ph.D., Independent Director (Age 84)
How do I buy Elite Pharmaceuticals stock?
Shares of Elite Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Elite Pharmaceuticals' stock price today?
One share of Elite Pharmaceuticals stock can currently be purchased for approximately $0.11.
How big of a company is Elite Pharmaceuticals?
Elite Pharmaceuticals has a market capitalization of $92.29 million and generates $9.64 million in revenue each year. The specialty pharmaceutical company earns $3.81 million in net income (profit) each year or ($0.01) on an earnings per share basis. Elite Pharmaceuticals employs 46 workers across the globe.
How can I contact Elite Pharmaceuticals?
Elite Pharmaceuticals' mailing address is 165 LUDLOW AVENUE, NORTHVALE NJ, 07647. The specialty pharmaceutical company can be reached via phone at 201-750-2646 or via email at [email protected]
MarketBeat Community Rating for Elite Pharmaceuticals (ELTP)MarketBeat's community ratings are surveys of what our community members think about Elite Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Elite Pharmaceuticals (OTCMKTS:ELTP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Elite Pharmaceuticals (OTCMKTS:ELTP) Earnings History and Estimates Chart
Elite Pharmaceuticals (OTCMKTS ELTP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018|| || || || || || || || |
Elite Pharmaceuticals (OTCMKTS:ELTP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Elite Pharmaceuticals (OTCMKTS:ELTP)
No dividend announcements for this company have been tracked by MarketBeat.com
Elite Pharmaceuticals (OTCMKTS ELTP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 34.66%
Institutional Ownership Percentage: 0.01%
Elite Pharmaceuticals (OTCMKTS ELTP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/18/2016||Jerry Treppel||Chairman||Sell||570,520||$0.34||$193,976.80||7,898,651|| |
|2/24/2016||Jerry Treppel||Chairman||Sell||200,456||$0.32||$64,145.92||8,311,537|| |
|2/17/2016||Jerry Treppel||Chairman||Sell||909,878||$0.33||$300,259.74||8,411,537|| |
|11/18/2015||Jerry Treppel||Chairman||Sell||150,000||$0.30||$45,000.00||9,196,769|| |
|4/27/2015||Douglas Plassche||VP||Sell||85,530||$0.24||$20,527.20|| |
|9/26/2014||Nasrat A Hakim||CEO||Buy||700,000||$0.31||$217,000.00|| |
|4/2/2014||Jeenarine Narine||Director||Sell||147,664||$0.41||$60,542.24|| |
|3/27/2014||Jeenarine Narine||Director||Sell||190,172||$0.43||$81,773.96|| |
|3/7/2014||Epic Pharma Llc||Major Shareholder||Sell||1,824,500||$0.77||$1,404,865.00|| |
|11/19/2013||Jeenarine Narine||Director||Sell||1,974,140||$0.12||$236,896.80|| |
|10/29/2013||Epic Investments, Llc||Major Shareholder||Sell||931,000||$0.13||$121,030.00|| |
|10/29/2013||Jeenarine Narine||Director||Sell||204,820||$0.07||$14,337.40|| |
Elite Pharmaceuticals (OTCMKTS ELTP) News Headlines
|Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2018 Results - Earnings Call Transcript|
seekingalpha.com - November 13 at 11:36 AM
|Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017|
finance.yahoo.com - November 10 at 12:28 PM
|Elite Pharmaceuticals Inc. (ELTP) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - November 8 at 10:14 AM
|CORRECTING And REPLACING - Elite Pharmaceuticals, Inc.|
www.thestreet.com - November 8 at 6:08 AM
|Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Second Quarter Financial Results on September 10, 2017|
finance.yahoo.com - November 8 at 6:08 AM
|CORRECTING and REPLACING – Elite Pharmaceuticals, Inc.|
finance.yahoo.com - November 8 at 6:08 AM
|Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release|
finance.yahoo.com - September 20 at 7:09 PM
|Elite Pharmaceuticals to Present ELI-200 (SequestOx™) Data at PAINWeek 2017 National Conference|
finance.yahoo.com - August 30 at 7:29 PM
|Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q1 2018 Results - Earnings Call Transcript|
seekingalpha.com - August 12 at 5:33 PM
|Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call Information|
finance.yahoo.com - August 9 at 6:24 PM
|Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss First Quarter Financial Results on August 10, 2017|
finance.yahoo.com - August 8 at 5:59 PM
|Elite Announces Co-Development of Four Additional Products with SunGen Pharma|
finance.yahoo.com - July 28 at 8:17 PM
|Elite Announces New Development and License Agreement with SunGen Pharma LLC|
finance.yahoo.com - July 12 at 6:55 PM
|ITEK Disappoints, ALNY Maps Out ATLAS, ENTL Opens Wallet, D-day Nearing For OCUL|
www.rttnews.com - July 10 at 6:07 PM
|Elite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx™|
finance.yahoo.com - July 8 at 10:29 AM
|Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q4 2017 Results - Earnings Call Transcript|
seekingalpha.com - June 15 at 6:59 PM
|FinancialBuzz.com: Developments in the Biotechnology Market - PR Newswire (press release)|
www.prnewswire.com - February 16 at 7:43 AM
|Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - February 13 at 5:45 PM
|Q3 2017 Elite Pharmaceuticals Inc Earnings Release - After Market Close|
us.rd.yahoo.com - February 9 at 5:31 PM
|ELITE PHARMACEUTICALS INC /NV/ Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl|
biz.yahoo.com - February 9 at 5:31 PM
|Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017 - Nasdaq|
www.nasdaq.com - February 8 at 10:29 PM
|Elite Reports On SequestOx™ FDA End-of-Review Meeting - GlobeNewswire (press release)|
www.globenewswire.com - January 23 at 9:40 AM
|FinancialBuzz.com: Recent Developments in the World of Small Cap Companies - PR Newswire (press release)|
www.prnewswire.com - January 17 at 3:20 PM
|Trending Small Cap Companies With News|
www.prnewswire.com - January 10 at 5:53 PM
|Elite Provides Update on SequestOx™ New Drug Application - GlobeNewswire (press release)|
globenewswire.com - December 23 at 3:12 AM
|ELITE PHARMACEUTICALS INC /NV/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - December 22 at 10:10 PM
|1:02 pm Elite Pharma updates on status of SequestOx NDA|
us.rd.yahoo.com - December 22 at 5:08 PM
|Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo - GlobeNewswire (press release)|
globenewswire.com - December 14 at 8:44 AM
Elite Pharmaceuticals (OTCMKTS:ELTP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Elite Pharmaceuticals (OTCMKTS:ELTP) Income Statement, Balance Sheet and Cash Flow Statement
Elite Pharmaceuticals (OTCMKTS ELTP) Stock Chart for Saturday, January, 20, 2018